3-Year Bispecific Antibody Real World Experience Study | Jay Hydren, PhD, CSCS | #IMS2025

28 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Join our 3-Year Bispecific Antibody Study: https://healthtree.org/myeloma/community/bispecific-antibody-study
(Teclistamab (Tecvayli), Elranatamab (Elrexfio), Talquetamab (Talvey) or Linvoseltamab (Lynozyfic))

Clinical Trial Finder: https://healthtree.org/myeloma/community/clinical-trials

Watch the full course and our most up-to-date content here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree Cure Hub here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general

Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.
Categoria
Oncology
Commenta per primo questo video.

Prossimo